Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

QuidelOrtho

Develops, manufactures and markets rapid diagnostic tests that focus on infectious diseases, reproductive health, and... read more Featured Products: More products

Download Mobile App




FDA Clears Hand-Held Test for Bordetella Pertussis

By LabMedica International staff writers
Posted on 04 Jan 2015
The United States Food and Drug Administration (FDA) have cleared an accurate, easy-to-use molecular diagnostic assay for Bordetella Pertussis that employs a unique hand-held platform and requires no pre-extraction of DNA.

The incidence of whooping cough, the very contagious disease caused by B. More...
pertussis attaching to cilia that line part of the upper respiratory tract, has risen over the last few years. Whooping cough can cause serious illness in children and adults, and is most dangerous for infants and babies. Quidel Corporation (San Diego, CA, USA), a developer and provider of new diagnostic solutions, has received the FDA clearance for its AmpliVue Bordetella Assay to detect B. pertussis nucleic acids isolated from nasopharyngeal swab specimens obtained from patients suspected of having a respiratory tract infection attributable to B. pertussis.

AmpliVue Bordetella is an easy-to-use, self-contained, disposable molecular diagnostic test with superb clinical accuracy. The assay requires no upfront extraction of DNA and generates the result in approximately 75 minutes. The AmpliVue platform is based on Quidel’s novel Helicase Dependent Amplification (HDA) technology that enables rapid nucleic acid amplification without a thermal cycler. So, like all FDA-cleared AmpliVue assays, AmpliVue Bordetella is CLIA-classified as moderately complex and does not require investment in expensive thermocycling equipment. This benefit, plus less laboratory space requirements, can significantly lower cost when adopting new molecular testing methods.

"We are pleased to receive 510(k) clearance for our AmpliVue Bordetella Assay—our 5th assay in the AmpliVue format. We've shown that we can harness our proprietary HDA technology to develop fast, accurate molecular diagnostic assays with a menu that matters to our customers," said Douglas Bryant, president and CEO of Quidel, "Longer-term, we intend to leverage this technology for other molecular diagnostic applications that will be appealing to significant market segments and potentially to public health agencies worldwide."

Quidel's novel AmpliVue platform now enables laboratories of all sizes to perform highly sensitive and specific molecular tests, and currently has FDA clearance for B. Pertussis, C. difficile, Group A Strep, Group B Strep, HSV1 and HSV2.

Related Links:

Quidel Corporation



New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Sample Transportation System
Tempus1800 Necto
New
Clinical Chemistry System
P780
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Platelets sequester cfDNA during circulation (Murphy L. et al., Science, 2025; DOI: 10.1126/science.adp3971)

Platelets Could Improve Early and Minimally Invasive Detection of Cancer

Platelets are widely recognized for their role in blood clotting and scab formation, but they also play a crucial role in immune defense by detecting pathogens and recruiting immune cells.... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Pathology

view channel
image: Researchers Marco Gustav (right) and MD Nic G. Reitsam (left) discuss the study data (Photo courtesy of Anja Stübner/EKFZ)

AI Model Simultaneously Detects Multiple Genetic Colorectal Cancer Markers in Tissue Samples

Colorectal cancer is a complex disease influenced by multiple genetic alterations. Traditionally, studies and diagnostic tools have focused on predicting only one mutation at a time, overlooking the interplay... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.